Sunitinib and Reversible Posterior Leukoencephalopathy Syndrome: the usual suspect but not always the culprit. A case report.
Sunitinib is a vascular endothelium growth factor inhibitor. This agent may in some cases be associated with life-threatening complications. We report a case of a 64-year-old woman, with a topical recurrence of a papillary renal cell carcinoma (PRCC) who had been treated with sunitinib and presented...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2025-04-01
|
| Series: | Forum of Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/fco-2024-0002 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849225059838722048 |
|---|---|
| author | Katopodis Ourania Lerikou Maria Karagiorgis Georgios Arvanitakis Spyridon |
| author_facet | Katopodis Ourania Lerikou Maria Karagiorgis Georgios Arvanitakis Spyridon |
| author_sort | Katopodis Ourania |
| collection | DOAJ |
| description | Sunitinib is a vascular endothelium growth factor inhibitor. This agent may in some cases be associated with life-threatening complications. We report a case of a 64-year-old woman, with a topical recurrence of a papillary renal cell carcinoma (PRCC) who had been treated with sunitinib and presented with generalized convulsive status epilepticus. A diagnosis of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) was made, which was attributed to an abrupt cessation of antihypertensive medication, although there have been cases attributed to sunitinib. Interestingly, after her hypertension was controlled and her clinical symptoms and radiological findings resolved, sunitinib treatment was safely reintroduced, with a good clinical outcome. Aggressive treatment of hypertension allowed the reintroduction of sunitinib, in a case where there were no other significant treatment alternatives. Intensive follow-up and proactive management enabled a successful outcome. |
| format | Article |
| id | doaj-art-d4c9bcc347eb42a282c8405f6a3304ea |
| institution | Kabale University |
| issn | 1792-362X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Forum of Clinical Oncology |
| spelling | doaj-art-d4c9bcc347eb42a282c8405f6a3304ea2025-08-25T06:11:53ZengSciendoForum of Clinical Oncology1792-362X2025-04-01151141810.2478/fco-2024-0002Sunitinib and Reversible Posterior Leukoencephalopathy Syndrome: the usual suspect but not always the culprit. A case report.Katopodis Ourania0Lerikou Maria1Karagiorgis Georgios2Arvanitakis Spyridon3Department of Medical Oncology, Euroclinic of Athens, Athens, GreeceDepartment of Medical Oncology, Euroclinic of Athens, Athens, GreeceDepartment of Neurology, Euroclinic of Athens, Athens, GreeceDepartment of Medical Oncology, Euroclinic of Athens, Athens, GreeceSunitinib is a vascular endothelium growth factor inhibitor. This agent may in some cases be associated with life-threatening complications. We report a case of a 64-year-old woman, with a topical recurrence of a papillary renal cell carcinoma (PRCC) who had been treated with sunitinib and presented with generalized convulsive status epilepticus. A diagnosis of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) was made, which was attributed to an abrupt cessation of antihypertensive medication, although there have been cases attributed to sunitinib. Interestingly, after her hypertension was controlled and her clinical symptoms and radiological findings resolved, sunitinib treatment was safely reintroduced, with a good clinical outcome. Aggressive treatment of hypertension allowed the reintroduction of sunitinib, in a case where there were no other significant treatment alternatives. Intensive follow-up and proactive management enabled a successful outcome.https://doi.org/10.2478/fco-2024-0002sunitinibreversible posterior leukoencephalopathy syndromerenal cell carcinomahypertensionstatus epilepticus |
| spellingShingle | Katopodis Ourania Lerikou Maria Karagiorgis Georgios Arvanitakis Spyridon Sunitinib and Reversible Posterior Leukoencephalopathy Syndrome: the usual suspect but not always the culprit. A case report. Forum of Clinical Oncology sunitinib reversible posterior leukoencephalopathy syndrome renal cell carcinoma hypertension status epilepticus |
| title | Sunitinib and Reversible Posterior Leukoencephalopathy Syndrome: the usual suspect but not always the culprit. A case report. |
| title_full | Sunitinib and Reversible Posterior Leukoencephalopathy Syndrome: the usual suspect but not always the culprit. A case report. |
| title_fullStr | Sunitinib and Reversible Posterior Leukoencephalopathy Syndrome: the usual suspect but not always the culprit. A case report. |
| title_full_unstemmed | Sunitinib and Reversible Posterior Leukoencephalopathy Syndrome: the usual suspect but not always the culprit. A case report. |
| title_short | Sunitinib and Reversible Posterior Leukoencephalopathy Syndrome: the usual suspect but not always the culprit. A case report. |
| title_sort | sunitinib and reversible posterior leukoencephalopathy syndrome the usual suspect but not always the culprit a case report |
| topic | sunitinib reversible posterior leukoencephalopathy syndrome renal cell carcinoma hypertension status epilepticus |
| url | https://doi.org/10.2478/fco-2024-0002 |
| work_keys_str_mv | AT katopodisourania sunitinibandreversibleposteriorleukoencephalopathysyndrometheusualsuspectbutnotalwaystheculpritacasereport AT lerikoumaria sunitinibandreversibleposteriorleukoencephalopathysyndrometheusualsuspectbutnotalwaystheculpritacasereport AT karagiorgisgeorgios sunitinibandreversibleposteriorleukoencephalopathysyndrometheusualsuspectbutnotalwaystheculpritacasereport AT arvanitakisspyridon sunitinibandreversibleposteriorleukoencephalopathysyndrometheusualsuspectbutnotalwaystheculpritacasereport |